ACHV - התחייבויות לטווח ארוך של החברה Achieve Life Sciences, Inc

Achieve Life Sciences (ACHV) generates revenue based on bringing addiction treatment products to market, where plant-based cytisine plays a key role. The company's US laboratories are developing unique solutions against nicotine addiction, leveraging positive test results and a lack of alternatives. The molecule patent provides access to a high-margin segment, while long-term debt stands at 0.00. This chart illustrates the asset's market performance.

Investors assess long-term risks by analyzing liabilities with maturities exceeding one year. This metric aggregates all borrowed funds, determining the financial burden and the issuer's degree of dependence on creditors. The trend in the long-term debt valuation of Achieve Life Sciences (ACHV) allows for a comparison of leverage against industry standards. For Achieve Life Sciences (ACHV), this confirms management's ability to fund the development of the smoking cessation drug without a critical debt load.